The trials and tribulations of anti-il-5 . . . [4] (multiple letters)

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 3, 2002, Pages 575-576

  Hansel, Trevor T ^a   Sterk, Peter J ^a   Holgate, Stephen T ^a   Barnes, Peter J ^a   O'Byrne, Paul M ^a   Inman, Mark D ^a   Parameswaran, Krishnan ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CHEMOKINE RECEPTOR CCR3; EOTAXIN; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HISTAMINE RELEASE; HUMAN; LETTER; LUNG FUNCTION; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0036130529     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.122237     Document Type: Letter

References (2)

1. PM O'Byrne MD Inman K. Parameswaran The trials and tribulations of IL-5, eosinophils, and allergic asthma J Allergy Clin Immunol 108 2001 503 508
2. MJ Leckie A ten Brinke J Khan Z Diamant BJ O'Connor CM Walls Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148